Zoloft (Sertraline) and Persistent Pulmonary Hypertension of the Newborn (PPHN): Understanding the FDA Warning and Causation

Latest update (2025-12)

FDA enforcement record (Ongoing): Defective container - seal not adhering to bottles. [source]

From General Health Literacy to Targeted Medication Safety

The legacy of general health and science communication has long emphasized the importance of understanding medication safety within broad public health contexts. This foundational approach prioritizes clear, accessible information about therapeutic benefits and potential risks, fostering informed decision-making among diverse populations. Within this framework, the discussion of adverse effects has traditionally centered on common, well-documented outcomes, often framed in terms of patient demographics or dosage considerations. Transitioning from this general health perspective, a more focused inquiry emerges when examining specific pharmaceutical exposures and their potential implications for vulnerable populations. The case of Zoloft (sertraline) and its association with persistent pulmonary hypertension of the newborn (PPHN) exemplifies this shift. Here, the concern moves beyond broad medication safety to a targeted analysis of prenatal exposure and neonatal outcomes. This pivot requires a nuanced understanding of how a widely prescribed antidepressant may carry distinct risks during pregnancy, particularly regarding fetal development. The occupational dimension becomes relevant when considering healthcare professionals, pharmacists, and researchers who routinely handle or counsel about this medication. Their exposure—whether through direct patient care, drug preparation, or clinical decision-making—necessitates a specialized awareness of emerging safety data. Thus, the transition from general health literacy to occupational exposure concern involves recognizing that certain medication risks demand heightened vigilance among those whose professional roles intersect with prescribing, dispensing, or monitoring such therapies.

Zoloft Pharmacology and the Bridge to PPHN Risk

Zoloft (sertraline) is a selective serotonin reuptake inhibitor (SSRI) approved for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. The drug's pharmacology involves increasing serotonin levels in the synaptic cleft by blocking its reuptake, which is central to its therapeutic effects but also underlies potential adverse outcomes, including persistent pulmonary hypertension of the newborn (PPHN) when used during pregnancy. PPHN is a serious condition characterized by sustained pulmonary vascular resistance after birth, leading to right-to-left shunting of blood across the ductus arteriosus or foramen ovale and severe hypoxemia. Clinical presentation includes tachypnea, cyanosis, and respiratory distress within hours of delivery, often requiring intensive care and mechanical ventilation. Diagnosis is confirmed by echocardiography demonstrating elevated pulmonary artery pressure and right ventricular dysfunction. The condition carries significant morbidity and mortality, with long-term neurodevelopmental risks in survivors. The mechanistic pathway linking Zoloft to PPHN involves serotonin's role in pulmonary vascular development and tone. Serotonin is a potent vasoconstrictor and mitogen for pulmonary artery smooth muscle cells. In utero, elevated serotonin levels from maternal SSRI use may disrupt the normal transition from fetal to neonatal circulation by promoting pulmonary vasoconstriction and vascular remodeling. Animal studies and human placental models suggest that SSRIs, including sertraline, can inhibit serotonin transporter function in the placenta, increasing fetal serotonin exposure. This excess serotonin may activate 5-HT2B receptors on pulmonary vascular smooth muscle, leading to sustained contraction and hyperplasia, which impairs the normal drop in pulmonary vascular resistance after birth.

Evidence from FDA Adverse Event Reports and Clinical Trials

FDA adverse-event reports from the FAERS database list nausea, fatigue, drug ineffective, anxiety, headache, depression, pain, diarrhoea, dizziness, dyspnoea, insomnia, asthenia, vomiting, fall, feeling abnormal, off label use, malaise, weight increased, arthralgia, weight decreased, tremor, suicidal ideation, somnolence, drug hypersensitivity, and back pain as the most frequently reported adverse events associated with Zoloft (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:ZOLOFT). While PPHN is not among the top reported events in this dataset, the FAERS system is a passive surveillance tool that may underreport rare or underrecognized adverse outcomes. The clinical trials data for Zoloft, derived from 3066 adults exposed for 8 to 12 weeks, do not include pediatric or neonatal outcomes, as these trials focused on adult psychiatric indications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe9e8b7d-61ea-409d-84aa-3ebd79a046b5). The most common adverse reactions in these trials were nausea, diarrhea/loose stool, tremor, dyspepsia, decreased appetite, hyperhidrosis, ejaculation failure, and decreased libido (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fda754f6-d0f3-4dce-a17a-927d64f912f7). These data do not directly address PPHN risk, as the trials excluded pregnant women.

FDA Warning and Adequacy of Risk Communication

The adequacy of warnings regarding Zoloft and PPHN is a critical risk anchor. The FDA has issued a warning about the potential increased risk of PPHN in infants exposed to SSRIs, including sertraline, during pregnancy. This warning is based on epidemiological studies that have reported an approximate twofold increased risk of PPHN with late-pregnancy SSRI use. However, the absolute risk remains low, with estimates of 1 to 2 cases per 1000 live births in the general population, rising to 3 to 4 per 1000 with SSRI exposure. The Zoloft prescribing information includes a section on use in pregnancy, but the specific PPHN warning may not be prominently featured in all labeling versions. The adequacy of these warnings is debated, as some clinicians and patients may not be fully aware of the risk, particularly given the absence of PPHN in the common adverse reactions listed in clinical trial data.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients require careful evaluation of the timeline between exposure and documented harm. PPHN typically presents within hours to days after birth, and exposure to Zoloft during the third trimester is the period of highest concern. The biological plausibility is supported by the mechanistic pathway described above, but establishing causation in individual cases is challenging due to confounding factors such as maternal depression itself, which is associated with adverse pregnancy outcomes, and the potential for other medications or comorbidities. The temporal relationship is consistent with a drug effect, as the condition manifests shortly after birth, coinciding with the peak fetal exposure from maternal use. However, the lack of a clear dose-response relationship in epidemiological studies and the rarity of the event complicate definitive attribution. In summary, the evidence supports a plausible mechanistic link between Zoloft and PPHN, with epidemiological data suggesting a modest increased risk. The adequacy of warnings is an ongoing concern, as the risk is not captured in the common adverse reactions from clinical trials. For affected patients, the timeline of exposure in late pregnancy and the acute presentation of PPHN at birth are consistent with a drug-related effect, but causation must be assessed on a case-by-case basis, considering all contributing factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Zoloft and PPHN?

The FDA has issued a warning that use of SSRIs like Zoloft (sertraline) during pregnancy, particularly in the third trimester, may increase the risk of persistent pulmonary hypertension of the newborn (PPHN). The warning is based on epidemiological studies showing an approximate twofold increased risk, though the absolute risk remains low (3-4 per 1000 live births with exposure vs. 1-2 per 1000 without).

How does Zoloft cause PPHN?

The proposed mechanism involves serotonin's role in pulmonary vascular development. Zoloft inhibits serotonin reuptake, increasing serotonin levels in the fetal circulation. Excess serotonin can cause pulmonary vasoconstriction and vascular remodeling via 5-HT2B receptors, impairing the normal drop in pulmonary vascular resistance after birth and leading to PPHN.

What are the symptoms of PPHN in newborns?

Symptoms include tachypnea (rapid breathing), cyanosis (bluish skin color), and respiratory distress within hours of delivery. Diagnosis is confirmed by echocardiography showing elevated pulmonary artery pressure and right ventricular dysfunction. PPHN requires intensive care and mechanical ventilation, and carries risks of long-term neurodevelopmental issues.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Zoloft exposure and a confirmed PPHN diagnosis may request an independent eligibility review. [Begin Assessment]

Zoloft PPHN lawsuit settlement criteria

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.